HRP20200046T1 - Formulacije apiksabana - Google Patents
Formulacije apiksabana Download PDFInfo
- Publication number
- HRP20200046T1 HRP20200046T1 HRP20200046TT HRP20200046T HRP20200046T1 HR P20200046 T1 HRP20200046 T1 HR P20200046T1 HR P20200046T T HRP20200046T T HR P20200046TT HR P20200046 T HRP20200046 T HR P20200046T HR P20200046 T1 HRP20200046 T1 HR P20200046T1
- Authority
- HR
- Croatia
- Prior art keywords
- tablet
- apixaban
- tablets
- mixing
- less
- Prior art date
Links
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 title claims 12
- 229960003886 apixaban Drugs 0.000 title claims 12
- 239000000203 mixture Substances 0.000 title claims 10
- 238000009472 formulation Methods 0.000 title claims 3
- 239000002245 particle Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- 238000002356 laser light scattering Methods 0.000 claims 4
- 239000002994 raw material Substances 0.000 claims 4
- 238000004090 dissolution Methods 0.000 claims 3
- 238000007922 dissolution test Methods 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 3
- 238000005469 granulation Methods 0.000 claims 3
- 230000003179 granulation Effects 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000012736 aqueous medium Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000007908 dry granulation Methods 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 230000009424 thromboembolic effect Effects 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 1
- 239000012738 dissolution medium Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
Claims (10)
1. Tableta koja sadrži do 5 mg kristalnih čestica apiksabana koje imaju D90 manji od 89 µm, kao što je mjereno rasipanjem laserske svjetlosti, i farmaceutski prihvatljiv razblaživač ili nosač, gdje formulacija pokazuje svojstva otapanja takva da se količina lijeka koja je ekvivalentna sa najmanje 77% otapa u roku od 30 minuta, pri čemu se test otapanja izvodi u vodenom mediju puferiranom na pH opseg 1 do 7.4 i kontroliran je na 37° C.
2. Tableta kao što je definirano u patentnom zahtjevu 1, gdje
(a) rezultat je utvrđen kao prosjek od 6 tableta; i/ili
(b) test otapanja je izveden u 900 mL medija za otapanje koji sadrži 0.05 M natrij fosfata pri pH 6.8 sa 0.05% SDS na 37 °C upotrebom USP aparata 2 (lopatice) pri brzini rotacije od 75 o/min i uzorci su analizirani za apiksaban pomoću HPLC na 280 nm.
3. Tableta kao što je definirano u patentnom zahtjevu 1 ili 2, gdje navedena kompozicija sadrži oblik N-1 apiksabana.
4. Tableta kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 3, gdje je apiksaban u obliku kristalnih čestica koje imaju D90 manji od 50 µm, D90 manji od 30 µm ili D90 manji od 25 µm kao što je mjereno rasipanjem laserske svjetlosti.
5. Tableta kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 4, gdje je apiksaban u obliku kristalnih čestica koje imaju srednju vrijednost veličine čestice manju od 89 µm kao što je mjereno rasipanjem laserske svjetlosti.
6. Tableta za upotrebu u liječenju tromboembolijskog poremećaja, gdje tableta je tableta kao što je definirano u jednom od patentnih zahtjeva 1 do 5.
7. Tableta za upotrebu u liječenju tromboembolijskog poremećaja kao što je definirano u patentnom zahtjevu 6, gdje je tableta administrirana oralno dva puta dnevno.
8. Postupak proizvodnje tableta apiksabana, gdje svaka tableta ima kompoziciju koja sadrži do 5 mg kristalnih čestica apiksabana i farmaceutski prihvatljiv razblaživač ili nosač, koji obuhvaća korake:
(1) miješanja sirovih materijala potrebno prije granulacije;
(2) granulacija sirovih materijala iz koraka (1) primjenom procesa suhe granulacije, pri čemu čestice apiksabana imaju D90 manji od 89 µm kao što je mjereno sa rasipanjem laserske svjetlosti;
(3) miješanja granula određene veličine iz koraka (2) sa ekstragranularnim sirovim materijalima;
(4) komprimiranja smjese iz koraka (3) u tablete; i
(5) oblaganja filmom tableta iz koraka (4),
gdje formulacija pokazuje svojstva otapanja takva da se količina lijeka koja je ekvivalentna sa najmanje 77% otapa u roku od 30 minuta, pri čemu se test otapanja izvodi u vodenom mediju puferiranom na pH opseg 1 do 7.4 i kontroliran je na 37° C.
9. Postupak proizvodnje tableta apiksabana kao što je definirano u patentnom zahtjevu 8, pri čemu su svojstva otapanja utvrđena kao prosjek od 6 tableta.
10. Postupak proizvodnje tableta apiksabana kao što je definirano u patentnom zahtjevu 8 ili 9 koji obuhvaća korake:
(1) miješanja sirovih materijala, sa apiksabanom kontrolirane veličine čestica;
(2) uključivanja intragranularnih dijelova vezujućeg sredstva, sredstva za raspadanje i drugih punilaca u smjesu iz koraka (1);
(3) granulacije materijala iz koraka (2) korištenjem postupka suhe granulacije koji obuhvaća:
(a) uklanjanje grudica iz intragranularnog lubrikanta upotrebom pogodnog sita ili mlina;
(b) dodavanje lubrikanta smjesi iz koraka (2) i miješanje;
(c) sabijanje ovlažene smjese u trake gustoće u opsegu od 1.1 do 1.2 g/cm3 i formiranje do dane veličine sabijenih traka upotrebom valjak kompaktora;
(4) miješanja granula određene veličine iz koraka (3) i ekstragranularnog sredstva za raspadanje u odgovarajućoj mješalici;
(5) uklanjanja grudica iz ekstragranularnog lubrikanta upotrebom pogodnog sita/mlina i miješanje sa granulama iz koraka (4);
(6) komprimiranja smjese iz (5) u tablete;
(7) oblaganja filmom tableta iz koraka (6).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30805610P | 2010-02-25 | 2010-02-25 | |
| EP17175864.2A EP3246021B1 (en) | 2010-02-25 | 2011-02-24 | Apixaban formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200046T1 true HRP20200046T1 (hr) | 2020-03-20 |
Family
ID=43901603
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160179TT HRP20160179T1 (hr) | 2010-02-25 | 2016-02-19 | Formulacije apiksabana |
| HRP20190430TT HRP20190430T8 (hr) | 2010-02-25 | 2019-03-05 | Formulacije apiksabana |
| HRP20192064TT HRP20192064T1 (hr) | 2010-02-25 | 2019-11-15 | Formulacije apiksabana |
| HRP20192069TT HRP20192069T1 (hr) | 2010-02-25 | 2019-11-18 | Formulacije apiksabana |
| HRP20200046TT HRP20200046T1 (hr) | 2010-02-25 | 2020-01-13 | Formulacije apiksabana |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160179TT HRP20160179T1 (hr) | 2010-02-25 | 2016-02-19 | Formulacije apiksabana |
| HRP20190430TT HRP20190430T8 (hr) | 2010-02-25 | 2019-03-05 | Formulacije apiksabana |
| HRP20192064TT HRP20192064T1 (hr) | 2010-02-25 | 2019-11-15 | Formulacije apiksabana |
| HRP20192069TT HRP20192069T1 (hr) | 2010-02-25 | 2019-11-18 | Formulacije apiksabana |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US9326945B2 (hr) |
| EP (7) | EP3662899A1 (hr) |
| JP (4) | JP5846647B2 (hr) |
| KR (4) | KR20210124532A (hr) |
| CN (3) | CN109602716A (hr) |
| AU (1) | AU2011220775B2 (hr) |
| BR (1) | BR112012021337A8 (hr) |
| CA (1) | CA2791171C (hr) |
| CO (1) | CO6640207A2 (hr) |
| CY (5) | CY1117434T1 (hr) |
| DK (5) | DK2538925T3 (hr) |
| ES (5) | ES2757603T3 (hr) |
| HK (5) | HK1180248A1 (hr) |
| HR (5) | HRP20160179T1 (hr) |
| HU (4) | HUE047140T2 (hr) |
| IL (3) | IL309564A (hr) |
| IN (1) | IN2012DN06587A (hr) |
| LT (4) | LT3251660T (hr) |
| MX (3) | MX353145B (hr) |
| NZ (1) | NZ601738A (hr) |
| PE (3) | PE20160042A1 (hr) |
| PL (5) | PL3017811T3 (hr) |
| PT (5) | PT3257500T (hr) |
| RS (5) | RS59810B1 (hr) |
| RU (1) | RU2685724C2 (hr) |
| SG (2) | SG10201501349VA (hr) |
| SI (5) | SI2538925T1 (hr) |
| SM (1) | SMT201600049B (hr) |
| TR (1) | TR201903195T4 (hr) |
| WO (1) | WO2011106478A2 (hr) |
| ZA (1) | ZA201205807B (hr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2757603T3 (es) | 2010-02-25 | 2020-04-29 | Bristol Myers Squibb Holdings Ireland | Formulaciones de apixabán |
| WO2013164839A2 (en) * | 2012-03-06 | 2013-11-07 | Cadila Healthcare Limited | Amorphous form of apixaban, process of preparation and compositions thereof |
| EP2854759B1 (en) * | 2012-05-24 | 2019-12-18 | ratiopharm GmbH | Dosage forms comprising apixaban and matrix former |
| WO2014052678A1 (en) | 2012-09-26 | 2014-04-03 | Bristol-Myers Squibb Company | Apixaban liquid formulations |
| CN102908324A (zh) * | 2012-10-31 | 2013-02-06 | 南京正科制药有限公司 | 一种阿哌沙班片 |
| EP2752414A1 (en) | 2013-01-04 | 2014-07-09 | Sandoz AG | Crystalline form of apixaban |
| CZ2013305A3 (cs) | 2013-04-23 | 2014-11-05 | Zentiva, K.S. | Nové krystalické formy APIXABANU a způsob jejich přípravy |
| US20160113912A1 (en) * | 2013-06-18 | 2016-04-28 | Cadila Healthcare Limited | An improved process for the preparation of apixaban and intermediates thereof |
| EP2907507A1 (en) * | 2014-02-17 | 2015-08-19 | Sandoz Ag | Pharmaceutical composition comprising apixaban |
| CN103830199A (zh) * | 2014-03-24 | 2014-06-04 | 重庆东得医药科技有限公司 | 含阿哌沙班的药用制剂及其制备方法 |
| CN104316637B (zh) * | 2014-10-30 | 2016-08-17 | 江苏宝众宝达药业有限公司 | 高效液相色谱法测定阿哌沙班清洗残留量 |
| US9603846B2 (en) | 2014-11-25 | 2017-03-28 | Cadila Healthcare Limited | Process for the preparation of apixaban |
| WO2016181276A1 (en) * | 2015-05-08 | 2016-11-17 | Wockhardt Limited | Stable pharmaceutical compositions comprising antibacterial agent |
| EP3380083A1 (en) | 2015-11-26 | 2018-10-03 | Zentiva, K.S. | Preparation of a drug form containing amorphous apixaban |
| CN106913528A (zh) * | 2015-12-25 | 2017-07-04 | 中美华世通生物医药科技（武汉）有限公司 | 阿哌沙班微丸及其制备方法 |
| CN108472261B (zh) * | 2016-01-12 | 2021-12-03 | 广东东阳光药业有限公司 | 阿哌沙班固体组合物及其制备方法 |
| EP3195860A1 (de) * | 2016-01-22 | 2017-07-26 | STADA Arzneimittel AG | Verfahren zur herstellung eines apixaban-granulates |
| WO2017163170A1 (en) * | 2016-03-21 | 2017-09-28 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition comprising apixaban |
| WO2017182908A1 (en) * | 2016-04-18 | 2017-10-26 | Emcure Pharmaceuticals Limited | Pharmaceutical compositions of apixaban |
| EP3243505A1 (en) | 2016-05-13 | 2017-11-15 | Zaklady Farmaceutyczne Polpharma SA | A pharmaceutical composition comprising amorphous apixaban |
| CN106822006B (zh) * | 2016-06-08 | 2020-08-28 | 北京普德康利医药科技发展有限公司 | 一种阿哌沙班片及其制备方法 |
| WO2017221209A1 (en) | 2016-06-23 | 2017-12-28 | Lupin Limited | Pharmaceutical formulations of apixaban |
| EA201990668A1 (ru) * | 2016-09-24 | 2019-10-31 | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| CN106420651B (zh) * | 2016-09-28 | 2019-03-08 | 乐普药业股份有限公司 | 一种阿哌沙班片的制备方法 |
| EP3582777A4 (en) | 2017-02-17 | 2020-12-23 | Unichem Laboratories Ltd | PHARMACEUTICAL COMPOSITION OF APIXABAN |
| CN111212859B (zh) | 2017-11-27 | 2023-06-06 | 三菱化学株式会社 | 含橡胶接枝聚合物、含有含橡胶接枝聚合物的树脂组合物及其成形体 |
| KR20190075566A (ko) | 2017-12-21 | 2019-07-01 | 전자부품연구원 | 다중 센서를 활용한 용변 습관 모니터링 시스템 및 방법 |
| TR201722523A2 (tr) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Api̇ksaban i̇çeren kati oral farmasöti̇k kompozi̇syonlar |
| CN108236604A (zh) * | 2018-02-07 | 2018-07-03 | 中国药科大学 | 阿哌沙班柔性脂质体 |
| CA3097176A1 (en) | 2018-04-16 | 2019-10-24 | Bristol-Myers Squibb Company | Apixaban formulations |
| KR20190130411A (ko) | 2018-05-14 | 2019-11-22 | 신일제약주식회사 | 아픽사반 약제학적 제제 및 그의 제조방법 |
| CA3109007A1 (en) | 2018-08-14 | 2020-02-20 | Jiangsu Hengrui Medicine Co., Ltd. | Injectable pharmaceutical composition and preparation method therefor |
| EP3666773A1 (en) | 2018-12-11 | 2020-06-17 | KRKA, D.D., Novo Mesto | Process for preparing apixaban |
| EP3669866A1 (en) | 2018-12-19 | 2020-06-24 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising apixaban |
| CN111377915B (zh) * | 2018-12-30 | 2023-10-24 | 鲁南制药集团股份有限公司 | 一种吡唑并-吡啶酮化合物晶型d |
| CN109464415B (zh) * | 2019-01-09 | 2021-08-17 | 常州恒邦药业有限公司 | 阿哌沙班药物组合物及其制备方法 |
| CN111214442B (zh) * | 2020-02-13 | 2021-12-10 | 山东百诺医药股份有限公司 | 一种阿哌沙班共微粉化物 |
| CN111494326A (zh) * | 2020-04-11 | 2020-08-07 | 南京正大天晴制药有限公司 | 一种阿哌沙班片及其制备方法 |
| EP4251155A1 (en) * | 2020-11-27 | 2023-10-04 | Santa Farma Ilac Sanayii A.S. | Improved wet granulation processes for apixaban comprising formulations |
| TR202100250A2 (tr) | 2021-01-08 | 2022-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Api̇ksaban i̇çeren fi̇lm kapli tablet |
| WO2022150030A2 (en) | 2021-01-08 | 2022-07-14 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A film coated tablet of apixaban |
| GB202102575D0 (en) | 2021-02-23 | 2021-04-07 | Teva Pharmaceutical Industries Ltd | Fixed-dose pharmaceutical compositions |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150366A (en) | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
| BR9917080A (pt) | 1998-12-23 | 2002-03-12 | Du Pont Pharm Co | Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica |
| PL204263B1 (pl) | 2001-09-21 | 2009-12-31 | Bristol Myers Squibb Co | Pochodna 1H-pirazolo[3,4-c]pirydyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie |
| TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| WO2004084943A1 (en) * | 2003-03-19 | 2004-10-07 | Beth Israel Deaconess Medical Center, Inc | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation |
| US20050059719A1 (en) * | 2003-09-16 | 2005-03-17 | Badawy Sherif Ibrahim Farag | Solid dosage formulation containing a Factor Xa inhibitor and method |
| DE10355461A1 (de) * | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| US7434502B2 (en) | 2004-07-21 | 2008-10-14 | Husqvarna Outdoor Products Inc. | Bar knob with cam-operated locking mechanism |
| US20060016084A1 (en) * | 2004-07-24 | 2006-01-26 | Ching-Lin Liao | Laser-Based datum instrument |
| US7396932B2 (en) * | 2004-09-28 | 2008-07-08 | Bristol-Myers Squibb Company | Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| US20060160841A1 (en) * | 2005-01-19 | 2006-07-20 | Chenkou Wei | Crystallization via high-shear transformation |
| GB0507577D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| US20070191306A1 (en) | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| US9034381B2 (en) | 2005-11-10 | 2015-05-19 | Alphapharm Pty Ltd | Process to control particle size |
| US20070259913A1 (en) | 2006-05-04 | 2007-11-08 | David Deitchman | Prophylaxis of thromboembolic events in cancer patients |
| CL2007002618A1 (es) * | 2006-09-12 | 2008-03-14 | Glaxo Group Ltd | Composicion farmaceutica de liberacion modificada oral que comprende una pluralidad de mini-comprimidos con un diametro menor que 5 mm y comprendiendo un inhibidor del factor xa dentro de una matriz de uno o mas polimeros; procedimiento de preparacio |
| FI20080351A0 (fi) | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi |
| EP2146705B1 (en) * | 2007-05-02 | 2014-03-05 | Portola Pharmaceuticals, Inc. | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
| US20090123390A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Compositions for the treatment of gastrointestinal inflammation |
| EP2291233B1 (en) * | 2008-05-09 | 2019-09-04 | Atacama Labs Oy | Method for dry granulation |
| KR20110043655A (ko) * | 2008-07-11 | 2011-04-27 | 바스프 에스이 | 모폴로지 변경제로서의 양친매성 단백질 |
| US20100018486A1 (en) * | 2008-07-22 | 2010-01-28 | Hung-Tao Liu | Cathode energy fuel-saving device |
| RU2624506C2 (ru) * | 2009-04-29 | 2017-07-04 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способы их применения |
| HUE048542T2 (hu) | 2009-06-16 | 2020-08-28 | Pfizer | Apixaban adagolási formái |
| ES2757603T3 (es) * | 2010-02-25 | 2020-04-29 | Bristol Myers Squibb Holdings Ireland | Formulaciones de apixabán |
| US9211258B2 (en) * | 2010-03-10 | 2015-12-15 | Lupin Limited | Rifaximin ready-to-use suspension |
-
2011
- 2011-02-24 ES ES17178613T patent/ES2757603T3/es active Active
- 2011-02-24 US US13/579,796 patent/US9326945B2/en active Active
- 2011-02-24 RS RS20200017A patent/RS59810B1/sr unknown
- 2011-02-24 KR KR1020217031947A patent/KR20210124532A/ko not_active Application Discontinuation
- 2011-02-24 HU HUE17178613A patent/HUE047140T2/hu unknown
- 2011-02-24 NZ NZ601738A patent/NZ601738A/en unknown
- 2011-02-24 PT PT171786130T patent/PT3257500T/pt unknown
- 2011-02-24 HU HUE17175788A patent/HUE047139T2/hu unknown
- 2011-02-24 PL PL15190823T patent/PL3017811T3/pl unknown
- 2011-02-24 EP EP20151141.7A patent/EP3662899A1/en active Pending
- 2011-02-24 JP JP2012555127A patent/JP5846647B2/ja active Active
- 2011-02-24 PL PL17175864T patent/PL3246021T3/pl unknown
- 2011-02-24 ES ES11707284.3T patent/ES2562279T3/es active Active
- 2011-02-24 PE PE2015002402A patent/PE20160042A1/es unknown
- 2011-02-24 IL IL309564A patent/IL309564A/en unknown
- 2011-02-24 DK DK11707284.3T patent/DK2538925T3/en active
- 2011-02-24 PT PT171758642T patent/PT3246021T/pt unknown
- 2011-02-24 EP EP15190823.3A patent/EP3017811B1/en active Active
- 2011-02-24 KR KR1020177031997A patent/KR20170126016A/ko not_active IP Right Cessation
- 2011-02-24 PL PL11707284T patent/PL2538925T3/pl unknown
- 2011-02-24 PL PL17175788T patent/PL3251660T3/pl unknown
- 2011-02-24 LT LT17175788T patent/LT3251660T/lt unknown
- 2011-02-24 SI SI201130742T patent/SI2538925T1/sl unknown
- 2011-02-24 LT LT17178613T patent/LT3257500T/lt unknown
- 2011-02-24 PE PE2012001362A patent/PE20130378A1/es not_active Application Discontinuation
- 2011-02-24 ES ES17175788T patent/ES2758031T3/es active Active
- 2011-02-24 CA CA2791171A patent/CA2791171C/en active Active
- 2011-02-24 EP EP17175788.3A patent/EP3251660B1/en active Active
- 2011-02-24 HU HUE11707284A patent/HUE027168T2/en unknown
- 2011-02-24 SI SI201131827T patent/SI3246021T1/sl unknown
- 2011-02-24 PE PE2020000316A patent/PE20210468A1/es unknown
- 2011-02-24 PT PT171757883T patent/PT3251660T/pt unknown
- 2011-02-24 LT LTEP15190823.3T patent/LT3017811T/lt unknown
- 2011-02-24 ES ES15190823T patent/ES2714363T3/es active Active
- 2011-02-24 EP EP17175864.2A patent/EP3246021B1/en active Active
- 2011-02-24 MX MX2015007763A patent/MX353145B/es unknown
- 2011-02-24 KR KR1020127022152A patent/KR101796300B1/ko active IP Right Review Request
- 2011-02-24 SG SG10201501349VA patent/SG10201501349VA/en unknown
- 2011-02-24 IN IN6587DEN2012 patent/IN2012DN06587A/en unknown
- 2011-02-24 DK DK17175788T patent/DK3251660T3/da active
- 2011-02-24 RS RS20191493A patent/RS59593B1/sr unknown
- 2011-02-24 BR BR112012021337A patent/BR112012021337A8/pt not_active Application Discontinuation
- 2011-02-24 DK DK17178613T patent/DK3257500T3/da active
- 2011-02-24 WO PCT/US2011/025994 patent/WO2011106478A2/en active Application Filing
- 2011-02-24 PL PL17178613T patent/PL3257500T3/pl unknown
- 2011-02-24 CN CN201810769647.9A patent/CN109602716A/zh active Pending
- 2011-02-24 KR KR1020237035193A patent/KR20230149861A/ko active Application Filing
- 2011-02-24 EP EP17178613.0A patent/EP3257500B1/en active Active
- 2011-02-24 SI SI201131665T patent/SI3017811T1/sl unknown
- 2011-02-24 PT PT117072843T patent/PT2538925E/pt unknown
- 2011-02-24 MX MX2017016605A patent/MX364938B/es unknown
- 2011-02-24 EP EP11707284.3A patent/EP2538925B1/en not_active Revoked
- 2011-02-24 CN CN201811354155.XA patent/CN109602713A/zh active Pending
- 2011-02-24 RS RS20191468A patent/RS59576B1/sr unknown
- 2011-02-24 CN CN201180011229XA patent/CN102770126A/zh active Pending
- 2011-02-24 RU RU2012140690A patent/RU2685724C2/ru active
- 2011-02-24 TR TR2019/03195T patent/TR201903195T4/tr unknown
- 2011-02-24 SG SG2012055547A patent/SG182750A1/en unknown
- 2011-02-24 HU HUE15190823A patent/HUE043932T2/hu unknown
- 2011-02-24 RS RS20160088A patent/RS54559B1/en unknown
- 2011-02-24 LT LTEP17175864.2T patent/LT3246021T/lt unknown
- 2011-02-24 RS RS20190290A patent/RS58699B1/sr unknown
- 2011-02-24 EP EP19199147.0A patent/EP3643301A1/en active Pending
- 2011-02-24 MX MX2012009244A patent/MX2012009244A/es active IP Right Grant
- 2011-02-24 AU AU2011220775A patent/AU2011220775B2/en active Active
- 2011-02-24 ES ES17175864T patent/ES2767848T3/es active Active
- 2011-02-24 SI SI201131811T patent/SI3251660T1/sl unknown
- 2011-02-24 SI SI201131813T patent/SI3257500T1/sl unknown
- 2011-02-24 DK DK17175864.2T patent/DK3246021T3/da active
- 2011-02-24 PT PT15190823T patent/PT3017811T/pt unknown
- 2011-02-24 DK DK15190823.3T patent/DK3017811T3/en active
-
2012
- 2012-07-22 IL IL221064A patent/IL221064A0/en unknown
- 2012-08-01 ZA ZA2012/05807A patent/ZA201205807B/en unknown
- 2012-09-05 CO CO12152138A patent/CO6640207A2/es not_active Application Discontinuation
-
2013
- 2013-07-02 HK HK13107697.6A patent/HK1180248A1/zh not_active IP Right Cessation
- 2013-07-02 HK HK16112621.4A patent/HK1224216A1/zh unknown
-
2015
- 2015-11-19 JP JP2015226794A patent/JP6033945B2/ja active Active
-
2016
- 2016-02-17 SM SM201600049T patent/SMT201600049B/xx unknown
- 2016-02-19 HR HRP20160179TT patent/HRP20160179T1/hr unknown
- 2016-03-07 CY CY20161100194T patent/CY1117434T1/el unknown
- 2016-03-31 US US15/086,447 patent/US20160243101A1/en not_active Abandoned
- 2016-10-26 JP JP2016209347A patent/JP6192078B2/ja active Active
-
2017
- 2017-03-30 US US15/474,264 patent/US20170202825A1/en not_active Abandoned
- 2017-03-30 US US15/474,236 patent/US20170202824A1/en not_active Abandoned
- 2017-04-27 IL IL251991A patent/IL251991A0/en unknown
- 2017-08-02 JP JP2017149644A patent/JP6577980B2/ja active Active
-
2018
- 2018-03-14 HK HK18103544.5A patent/HK1243947B/zh unknown
- 2018-03-14 HK HK18103543.6A patent/HK1243946A1/zh unknown
- 2018-03-14 HK HK18103542.7A patent/HK1243945B/zh unknown
-
2019
- 2019-02-28 CY CY20191100249T patent/CY1121597T1/el unknown
- 2019-03-05 HR HRP20190430TT patent/HRP20190430T8/hr unknown
- 2019-11-15 HR HRP20192064TT patent/HRP20192064T1/hr unknown
- 2019-11-18 HR HRP20192069TT patent/HRP20192069T1/hr unknown
- 2019-11-21 CY CY20191101226T patent/CY1122382T1/el unknown
- 2019-11-22 CY CY20191101231T patent/CY1122384T1/el unknown
-
2020
- 2020-01-13 HR HRP20200046TT patent/HRP20200046T1/hr unknown
- 2020-01-28 CY CY20201100074T patent/CY1122529T1/el unknown
- 2020-05-14 US US15/931,910 patent/US20200375968A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200046T1 (hr) | Formulacije apiksabana | |
| JP2013521226A5 (hr) | ||
| CN103371976B (zh) | 一种含塞来昔布的固体分散物及其制备方法 | |
| Gowthamarajan et al. | Preliminary study of Anacardium occidentale gum as binder in formulation of paracetamol tablets | |
| Srivastava et al. | Formulation and evaluation of Paracetamol tablets to assess binding property of orange peel pectin | |
| BRPI0606187A2 (pt) | comprimidos com capacidade de dispersão da substáncia do fármaco melhorada | |
| CN104288154A (zh) | 一种含有不同粒径范围的法匹拉韦药物组合物 | |
| WO2007097333A1 (ja) | 顆粒、錠剤およびそれらの製造方法 | |
| Patil et al. | Preparation and evaluation of Aegle marmelos gum as tablet binder | |
| Michie et al. | The influence of plate design on the properties of pellets produced by extrusion and spheronization | |
| KR20100063090A (ko) | 알리스키렌 및 발사르탄의 생약 제제 | |
| CN104288153A (zh) | 一种氟哌噻吨美利曲辛药物组合物及其制备方法 | |
| JP2008280268A (ja) | メコバラミン含有粉体 | |
| CN1279899C (zh) | 含支链氨基酸颗粒的生产方法 | |
| CA2648667A1 (en) | Sustained-release tablet production process | |
| CN106018618B (zh) | 草酸艾司西酞普兰片剂组合物和质控方法 | |
| Podczeck et al. | Influence of the standing time of the extrudate and speed of rotation of the spheroniser plate on the properties of pellets produced by extrusion and spheronization | |
| CN102764254A (zh) | 一种左乙拉西坦药物组合物及其制备方法 | |
| CN108014085A (zh) | 一种氨己烯酸固体组合物的制备方法及其应用 | |
| JP2007008872A (ja) | 造粒粒子の製造方法およびその造粒粒子、並びに固形製剤 | |
| CN1672705A (zh) | 裸花紫珠分散片及其制备方法 | |
| CN112999180B (zh) | 一种硫酸氢氯吡格雷晶型ⅱ片剂及其制备方法 | |
| CN105534980A (zh) | 瑞格列奈盐酸二甲双胍的药物组合物及其制剂工艺 | |
| TWI728709B (zh) | 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方 | |
| CN103989643A (zh) | 含有雷美替胺和共聚维酮的片剂 |